Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Greece

- PMLiVE

Novartis bags new breakthrough status for Kisqali in breast cancer

The Swiss pharma group’s treatment will rival Lilly’s Verzenio and Pfizer’s Ibrance if approved

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

Novartis Oncology head Bruno Strigini to retire

Will leave the Swiss pharma firm, and the industry, next year

- PMLiVE

CAR-T therapies show long-term benefits in lymphoma

Novartis’ Kymriah and Gilead’s Yescarta both achieve significant complete response in lymphoma patients

- PMLiVE

AAA board presses go on $3.9bn Novartis takeover

French radiopharmaceuticals firm backs the cash offer

- PMLiVE

Novartis’ orphan drug Tasigna wins EU expanded indication

The CML medication can now treat paediatric patients

National Institute for Health and Care Excellence NICE logo

NICE backs two advanced breast cancer drugs after price cuts

An estimated 8,000 women will be eligible to receive the drugs due to discounts

- PMLiVE

Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

Women on Kisqali were found to have a longer PFS than those on hormonal therapy alone

- PMLiVE

Novartis strengthens autoimmune indications for Cosentyx

Data shows its IL-17A inhibitor can reduce structural disease progression

- PMLiVE

Novartis files CAR-T therapy CTL109 in Europe

Analysts predict Kymriah could become a $1bn-plus product in Europe

Pharma’s digital patient engagement innovators identified

Novartis, Pfizer and Sanofi named best-in-class by Decision Resources Group

- PMLiVE

Novartis moves swiftly with lymphoma filing for CAR-T Kymriah

Will go up against Kite Pharma's Yescarta if approved

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links